**Title:** Rationale and Design of Extended Cancer Education for Longer Term Survivors (EXCELS): A Randomized Control Trial of ‘High Touch’ vs. ‘High Tech’ Cancer Survivorship Self-management Tools in Primary Care

**Authors:**

Stacy Davis (sdavis1908@yahoo.com; stacy.davis@rutgers.edu)

Denalee O’Malley (omalledm@rwjms.rutgers.edu)

Alicja Bator (alicjab@rwjms.rutgers.edu)

Pamela Ohman-Strickland (ohmanpa@sph.rutgers.edu)

Lynn Clemow (clemowlp@rwjms.rutgers.edu)

Jeanne Ferrante (ferranjm@rwjms.rutgers.edu)

Benjamin Crabtree (crabtrbf@rwjms.rutgers.edu)

Suzanne Miller (suzanne.miller@fccc.edu)

Patricia Findley (pfindley@ssw.rutgers.edu)

Shawna Hudson (hudsonsh@rwjms.rutgers.edu)

**Version:** 1  **Date:** 06 Mar 2019

**Author’s response to reviews:**

BMC Cancer requested the following changes and edits, which have been addressed below and in the revised manuscript. We thank you for reviewing and considering our manuscript for publication.

1. Clarification of ethics approval and participant consent to participate.

Written informed consent is obtained from study participants and we clarified this in our manuscript in the “Ethics and consent to participate” subsection of the “Declarations”. New language in the manuscript reads: Trial was approved by the Rutgers University Institutional Review Board and CentraState Healthcare System Institutional Review Board. All participants will provide written informed consent to participate in this trial.

2. Clarification of Ethical Approval and Documentation.
Ethical approval provided by the Rutgers University Institutional Review Board covers all study sites. One community site required additional local review of the study. We have forwarded a copy of the CentraState Medical Center ethical approval of the trial to the BMC Series Editorial@biomedcentral.com. We have also added language to the manuscript on page 6.

3. Clarification of trial Sample Size and expansion of study outcomes in the manuscript.

We submitted study information to clinicaltrials.gov upon initiation of the study. The sample size of 535 on clinicaltrials.gov reflects participants who were recruited to develop the intervention in phase 1 [N=30 BC, PC, CRC patients inclusive of concept development depth interviews, 10 clinician interviews and 15 user test participants]) and the phase 2 RCT participants (N=480). We have clarified this in the manuscript. As well, study outcomes are now described in detail in the manuscript in Table 2.

4. Clarification of Authors Contributions.

We have further specified the individual contributions of all authors to the manuscript in the “Declarations”. New language in the manuscript reads: SVH conceptualized the study, provided critical feedback and edits throughout the development of the article. SND drafted the first draft of the manuscript, constructed the tables/figure, and provided edits throughout. DO provided extensive feedback on the initial draft of the manuscript and provided edits throughout. AB, POS, LC, JMF, BFC, SMM, PC assisted in editing. All authors read and approved the final manuscript.